+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2014-01-24Number of Pages: 72

Ophthalmic Drugs Market (Dry eye, Anti-glaucoma, Anti-allergy/inflammatory/infective, Retinal Drugs) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2018

Globally, the ophthalmic drugs market is witnessing significant growth due to increasing prevalence of eye disorders such as diabetic retinopathy and macular degeneration. As a result, this market is expected to grow at a CAGR of about 5.2% during 2013 – 2018.

 

Some of the key driving factors for the ophthalmic drugs market are rising prevalence of global aging population, increasing government initiatives towards healthcare infrastructure in developing countries (such as India and China), technological changes in drug delivery technique, and increasing prevalence of lifestyle associated diseases. However, the market faces some restraints such as lack of awareness among people regarding eye disorders, drying pipeline of ophthalmic drugs, patent expiration of blockbuster ophthalmic drugs and absence of health insurance in developing countries. 

 

North America, including the US has the largest ophthalmic drugs market. Asia is the fastest growing ophthalmic drugs market. Some of the fastest growing markets for ophthalmic drugs are China, India, other countries in South East Asia and the Eastern Mediterranean. As per WHO estimates in 2010, in the next nine years, the number of blind people aged 50 years and above will grow in these regions, thereby increasing the demand for ophthalmic drugs. On the other hand, in developed regions such as North America and Western Europe, rising efforts towards prevention of blindness among the aging population has emerged as a key driver for the market

Glaucoma has the largest market share in the ophthalmic drugs market and it is expected to grow at a CAGR of about 4.2% during 2013 – 2018.Various ophthalmic drug companies are increasing their focus on combination therapy, which involves use of more than one medication for specific retinal disorders. Most of these combination therapies are used as first line treatment in patients with high level of intraocular pressure. Combination therapy has various advantages over traditional medication such as reduced frequency of eye drop application, improved patient compliance and efficacy.

 

Novartis (Alcon) is the leading player in the global ophthalmic drugs market with a share of about 24% in 2012. Other major players of ophthalmic drugs market include Allergan, Santen, Pfizer, Merck and Roche and others.

 

Chapter 1 Preface 8

1.1 Report Description 8

1.2 Research Methodology 8

 

Chapter 2 Executive Summary 10

 

Chapter 3 Ophthalmic Drugs – Industry Analysis 11

3.1 Introduction 11

3.2 Market Drivers and Opportunities 11

      3.2.1 Increasing prevalence of eye disorders 12

      3.2.2 Global aging population 12

      3.2.3 Rising government initiatives towards healthcare infrastructure in developing countries 13

      3.2.4 Technological changes in drug delivery techniques 14

      3.2.5 Increasing prevalence of lifestyle associated diseases 14

3.3 Restraints and Challenges 15

      3.3.1 Lack of awareness among people regarding eye disorders 15

      3.3.2 Drying pipeline of ophthalmic drugs 15

      3.3.3 Patent expiration of blockbuster ophthalmic drugs 16

      3.3.4 Absence of health insurance in developing countries 16

 

Chapter 4 Ophthalmic Drugs Market Trends 18

4.1 Increased focus on combination therapy 18

4.2 Increasing mergers and acquisitions contribute to the growth of ophthalmic drugs market 18

 

Chapter 5 Porter’s Five Force Analysis 20

5.1 Bargaining power of buyers 20

5.2 Bargaining power of suppliers 21

5.3 Threat of new entrants 21

5.4 Threat from substitutes 21

5.5 Degree of competition 21

 

Chapter 6 Global Market Size and Forecast 22

 

Chapter 7 Ophthalmic Drugs Market – Treatment Drugs 25

7.1 Dry eye drugs 25

      7.1.1 Existing 25

      7.1.2 Pipeline 26

7.2 Retinal drugs 27

      7.2.1 Existing 27

      7.2.2 Pipeline 28

7.3 Ophthalmic anti-allergy/ inflammatory/ infective drugs 29

      7.3.1 Existing 29

      7.3.2 Pipeline 30

7.4 Anti-glaucoma drugs 31

      7.4.1 Existing 31

      7.4.2 Pipeline 32

 

Chapter 8 Ophthalmic Drugs Market: Regional Analysis 34

8.1 Scenario in North America 34

      8.1.1 Scenario in the US 36

8.2 Scenario in Europe 38

      8.2.1 Scenario in France 41

      8.2.2 Scenario in Germany 42

      8.2.3 Scenario in the UK 44

8.3 Scenario in Asia Pacific 46

      8.3.1 Scenario in India 49

      8.3.2 Scenario in China 50

      8.3.3 Scenario in Japan 52

 

Chapter 9 Prescription vs. Over the Counter Drugs 55

 

Chapter 10 Competitive Landscape 57

 

Chapter 11 Company Profiles 62

11.1 Santen Pharmaceutical 62

      11.1.1 Overview 62

      11.1.2 Products and segments 62

      11.1.3 Financial Performance 62

11.2 Pfizer 63

      11.2.1 Overview 63

      11.2.2 Products & Segments 63

      11.2.3 Financial Performance 63

11.3 Novartis 64

      11.3.1 Overview 64

      11.3.2 Products & Segments 64

      11.3.3 Financial Performance 65

11.4 Merck 66

      11.4.1 Overview 66

      11.4.2 Products & Segments 66

      11.4.3 Financial Performance 66

11.5 Roche 68

      11.5.1 Overview 68

      11.5.2 Products & Segments 68

      11.5.3 Financial Performance 68

11.6 Allergan 70

      11.6.1 Overview 70

      11.6.2 Products & Segments 70

      11.6.3 Financial Performance 70

List of Figures 

 

FIG. 1 Profiles of aging population in major countries (%, 2000-2050) 13

FIG. 2 Global ophthalmic drugs market: Porter’s five force analysis 20

FIG. 3 Key players market share in the global ophthalmic drugs market in 2012 57

FIG. 4 Ophthalmic drugs market strategic developments (2011-2013) 58

List of Tables

 

TABLE 1 Drivers for ophthalmic drugs market: Impact analysis 11

TABLE 2 Global data on visual impairment, by region (million, 2002 and 2010) 12

TABLE 3 Restraints for ophthalmic drugs market: Impact analysis 15

TABLE 4 Out of pocket expenditure of developing and developed countries 17

TABLE 5 Major combination therapy drugs worldwide 18

TABLE 6 Major merger and acquisitions in the ophthalmic drug market 19

TABLE 7 Global Ophthalmic drugs market size, by geography 2008-2012 (USD million) 22

TABLE 8 Global Ophthalmic drugs market size, by geography 2013-2018(USD millions) 23

TABLE 9 Global Ophthalmic drugs market size, by disease 2008-2012 (USD million) 23

TABLE 10 Global Ophthalmic drugs market size, by disease 2013-2018 (USD million) 24

TABLE 11 Dry eye drugs market 2010-2012 (USD million) 25

TABLE 12 Dry eye drugs market 2013-2018 (USD million) 26

TABLE 13 Major dry eye drugs pipeline 26

TABLE 14 Retinal drugs market 2010-2012 (USD million) 27

TABLE 15 Retinal drugs market 2013-2018 (USD million) 28

TABLE 16 Major retinal disease drugs pipeline 28

TABLE 17 Anti-allergy/inflammatory drugs market 2010-2012 (USD million) 29

TABLE 18 Anti-allergy/inflammatory drugs market 2013-2018 (USD million) 30

TABLE 19 Major anti-inflammatory/allergy/anti-infective drugs pipeline 30

TABLE 20 Prevalence of glaucoma, by geographic regions (million, 2010-2020) 31

TABLE 21 Major anti-glaucoma drugs market 2010-2012 (USD million) 32

TABLE 22 Major anti-glaucoma drugs market 2013-2018 (USD million) 32

TABLE 23 Anti-glaucoma drugs pipeline 33

TABLE 24 North America Ophthalmic drugs market size, by geography 2008-2012 (USD million) 34

TABLE 25 North America Ophthalmic drugs market size, by geography 2013-2018 (USD million) 35

TABLE 26 North America Ophthalmic drugs market size, by disease 2008-2012 (USD million) 35

TABLE 27 North America ophthalmic drugs market, by disease 2013-2018 (USD million) 36

TABLE 28 Ophthalmic drugs market, by disease in US 2008-2012(USD million) 37

TABLE 29 Ophthalmic drugs market by disease in US 2013-2018 (USD million) 37

TABLE 30 European Ophthalmic drugs market size, by geography 2008-2012 (USD million) 38

TABLE 31 European Ophthalmic drugs market size, by geography 2013-2018 (USD million) 39

TABLE 32 European ophthalmic drugs market by disease 2008-2012 (USD million) 40

TABLE 33 European ophthalmic drugs market by disease 2013-2018 (USD million) 40

TABLE 34 French ophthalmic drugs market by disease 2008-2012 (USD million) 41

TABLE 35 French ophthalmic drugs market, by disease 2013-2018 (USD million) 42

TABLE 36 German Ophthalmic drugs market, by disease 2008-2012 (USD million) 43

TABLE 37 German ophthalmic drugs market, by disease 2013-2018 (USD million) 43

TABLE 38 The UK ophthalmic drugs market, by disease 2008-2012 (USD million) 45

TABLE 39 The UK ophthalmic drugs market, by disease 2013-2018 (USD million) 45

TABLE 40 Asian Ophthalmic drugs market size, by country 2008-2012 (USD million) 46

TABLE 41 Asian Ophthalmic drugs market size, by geography 2013-2018 (USD million) 47

TABLE 42 Asian ophthalmic drugs market, by disease 2008-2012 (USD million) 47

TABLE 43 Asian ophthalmic drugs market, by disease 2013-2018 (USD million) 48

TABLE 44 Indian ophthalmic drugs market, by disease 2008-2012 (USD million) 49

TABLE 45 Indian ophthalmic drugs market, by disease 2013-2018 (USD million) 50

TABLE 46 Chinese ophthalmic drugs market, by disease 2008-2012 (USD million) 51

TABLE 47 Chinese ophthalmic drugs market, by disease 2013-2018 (USD million) 52

TABLE 48 Japanese ophthalmic drugs market, by disease 2008-2012 (USD million) 53

TABLE 49 Japanese ophthalmic drugs market, by disease 2013-2018 (USD million) 53

TABLE 50 Ophthalmic drugs market, by prescription vs. over the counter drugs 2008-2012 (USD million) 55

TABLE 51 Ophthalmic drugs market, by prescription vs. over the counter drugs 2013-2018 (USD million) 56

TABLE 52 Major product launches in ophthalmic drugs market (2011-2013) 59

TABLE 53 R&D initiatives in ophthalmic drugs market (2012-2013) 60

TABLE 54 Mergers and acquisitions in ophthalmic drugs market (2011-2013) 61

Data released by the World Health Organization (WHO) reveals that 90% of the world’s visually impaired people reside in developing countries such as Mexico, Brazil, China, and India. It shows close to 285 mn are visually impaired across the world of whom 246 mn have low vision and 39 mn are blind. This is expected to boost the market of ophthalmology devices phenomenally. The global ophthalmic drugs market is predicted to attain a market value of US$21.6 bn by 2018. The report segments the market on various parameters, namely type of drugs, their various treatments, and geography. 

Using a lucid and comprehensive format, the research report studies past and current market trends to throw light on the future trajectory of the global ophthalmic drugs market. It leverages SWOT analysis to elaborate on the strengths, weaknesses, opportunities, and threats of prominent players, in particular and the industry, in general. It has been compiled after thorough primary and secondary research. Additionally, the report also talks about the latest research and development in the field of ophthalmic drugs, an in-depth financial overview, investment outlook, and product portfolio of key vendors. 

Overview of the Global Ophthalmic Drugs Market 

Ophthalmic drugs or ophthalmic medications are drops, intraocular disks, and ointments that are prescribed to patients with eye-related disorders. The last few years saw an impressive growth in the global ophthalmic drugs market. This is on account of high prevalence of eye disorders afflicting a growing number of diabetics, aging people, and those with macular degeneration. Reports suggest over 60 mn people suffer from glaucoma and this number would reach 80 mn by 2020. Such alarming numbers, coupled with rapid strides in technology, drug delivery methods, and rising awareness about lifestyle-related diseases, are driving the global ophthalmic drugs market. 

The global ophthalmic drugs market is segmented on the basis of type into prescription drugs and over-the-counter drugs. On the basis of the type of treatments they offer, the market can be divided into dry eye drugs, retinal drugs, allergy or infective drugs, anti-inflammatory, and anti-glaucoma drugs. Amongst treatment drugs, the anti-glaucoma drugs segment is leading the global ophthalmic treatment drugs market. Geographically, this market is segmented into Europe, North America, Asia Pacific, and Rest of the World. North America currently dominates the overall ophthalmic drugs market and is likely to retain its leading position, on account of initiatives being undertaken on a large scale to thwart blindness and other eye-related disorders, particularly in the aging population. The ophthalmic drugs market in Asia Pacific is also expected to register robust growth due to the high occurrence of ophthalmic disorders amongst geriatrics in the region. Further, economic development in the region on account will put more disposable income into the hands of the people, thereby enabling them to avail proper treatment. 

Lack of knowledge of diseases such as glaucoma, particularly in developing or backward economies, however, is hobbling growth of the global ophthalmic drugs market. Additionally, loss of patent protection for several drugs and drying pipeline would also led to losses of manufacturers. These restraints will be a drag on the grow rate of the market. 

Companies mentioned in the research report 

Some of the key players in the global ophthalmic drugs market are Novartis International AG., Santen Pharmaceutical Co. Ltd., Roche Holding AG, Merck & Co. Inc., Pfizer Inc., and Allergan Inc. 

Key Segments of the Global Ophthalmic Drugs Market 

By Types

  • Prescription Drugs
  • OTC Drugs

By Treatment Drugs

  • Dry Eye Drugs
  • Retinal Drugs
  • Anti-inflammatory/allergy/infective Drugs
  • Anti-glaucoma Drugs 

By Geography

  • Europe
  • North America
  • Asia Pacific
  • Rest of the World 

This report gives you access to decisive data such as:

  • Market growth drivers
  • Factors limiting market growth
  • Current market trends
  • Market structure
  • Market projections for the coming years 

Key highlights of this report

  • Overview of key market forces propelling and restraining market growth
  • Up-to-date analyses of market trends and technological improvements
  • Pin-point analysis of market competition dynamics to offer you a competitive edge
  • An analysis of strategies of major competitors
  • An array of graphics and SWOT analysis of major industry segments
  • Detailed analysis of industry trends
  • A well-defined technological growth map with an impact-analysis
  • Offers a clear understanding of the competitive landscape and key product segments


 
 
Back To Top